82 related articles for article (PubMed ID: 1684441)
1. Bromocriptine in augmentation of antipsychotic response in chronic schizophrenia: a negative pilot report.
Wells BG; Chu CC; Abi-Darghum A; Saini TS
Pharmacopsychiatry; 1991 Jul; 24(4):118-20. PubMed ID: 1684441
[TBL] [Abstract][Full Text] [Related]
2. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
Lombertie ER; Durelle G; Fuseau A
Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
5. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia.
Mori K; Nagao M; Yamashita H; Morinobu S; Yamawaki S
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):659-65. PubMed ID: 15276691
[TBL] [Abstract][Full Text] [Related]
6. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
[TBL] [Abstract][Full Text] [Related]
7. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
[TBL] [Abstract][Full Text] [Related]
8. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
[TBL] [Abstract][Full Text] [Related]
9. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
10. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
Loas G; Noisette C; Legrand A; Delahousse J
Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
[TBL] [Abstract][Full Text] [Related]
11. [Drug treatment of schizophrenic psychoses in puerperium].
Olbrich HM; Martin P
Nervenarzt; 1994 Jul; 65(7):482-5. PubMed ID: 7800093
[TBL] [Abstract][Full Text] [Related]
12. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
[TBL] [Abstract][Full Text] [Related]
13. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
14. [Incidence of the deficit form in refractory schizophrenia].
Samuelian JC
Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
[TBL] [Abstract][Full Text] [Related]
15. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
Nakanishi S; Kunugi H; Murray RM; Nojima S; Ogawa T; Takahashi T
Psychiatry Clin Neurosci; 2006 Dec; 60(6):751-7. PubMed ID: 17109710
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
[TBL] [Abstract][Full Text] [Related]
17. The effect of augmentation with moclobemide on symptoms of schizophrenia.
Silver H; Aharon N; Hausfater N; Jahjah N
Int Clin Psychopharmacol; 1999 May; 14(3):193-5. PubMed ID: 10435775
[TBL] [Abstract][Full Text] [Related]
18. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.
Suzuki K; Awata S; Takano T; Ebina Y; Iwasaki H; Matsuoka H
Psychiatry Clin Neurosci; 2005 Aug; 59(4):481-9. PubMed ID: 16048455
[TBL] [Abstract][Full Text] [Related]
19. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
[TBL] [Abstract][Full Text] [Related]
20. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
Henderson DC; Goff DC
J Clin Psychiatry; 1996 Sep; 57(9):395-7. PubMed ID: 9746446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
